Benitec Biopharma (BNTC) Revenue (2019 - 2023)

Benitec Biopharma has reported Revenue for 5 years, with the latest figure at $7000.0 in Q2 2023.

• Quarterly Revenue changed N/A year-over-year to $7000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $7000.0 (down 89.71% YoY) and the FY2023 annual result came in at $75000.0, up 2.74% from the prior year.
• Revenue fell to $7000.0 in Q2 2023 per BNTC's latest filing, from $54000.0 in the prior quarter.
• Over five years, Revenue peaked at $77000.0 in Q4 2019 and troughed at -$35000.0 in Q2 2020.
• A 5-year average of $23846.2 and a median of $25000.0 in 2021 frame the typical range for Revenue.
• The sharpest annual moves came in 2020 and 2022: Revenue tumbled 98.7% in 2020, then surged 4700.0% in 2022.
• Over 5 years, Revenue stood at $77000.0 in 2019, then sank by 98.7% to $1000.0 in 2020, then jumped by 2400.0% to $25000.0 in 2021, then slumped by 44.0% to $14000.0 in 2022, then slumped by 50.0% to $7000.0 in 2023.
• According to Business Quant data, Revenue over the past three periods registered $7000.0, $54000.0, and $14000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.